Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

G. W. Canonica; F. Blasi; P. Paggiaro; G. Senna; G. Passalacqua; A. Spanevello; S. Aliberti; D. Bagnasco; M. Bonavia; M. Bonini; L. Brussino; C. Bucca; M. F. Caiaffa; Anna Chiara Calabrese; G. Camiciottoli; M. Caminati; G. E. Carpagnano; C. Caruso; S. Centanni; M. E. Conte; A. G. Corsico; L. Cosmi; M. T. Costantino; N. Crimi; S. D'Alo; M. D'Amato; Giacco S. Del; A. Farsi; E. Favero; Barbaro M. P. Foschino; G. Guarnieri; G. Guida; M. Latorre; Cicero S. Lo; C. Lombardi; L. Macchia; F. Mazza; F. Menzella; M. Milanese; M. Montagni; Paolo Montuschi; E. Nucera; R. Parente; V. Patella; G. Pelaia; L. Pini; F. Puggioni; L. Ricciardi; F. L. M. Ricciardolo; Luca Richeldi; E. Ridolo; G. Rolla; P. Santus; N. Scichilone; G. Spadaro; A. Vianello; V. Viviano; M. R. Yacoub; M. C. Zappa; E. Heffler

doi:10.1016/j.waojou.2020.100464

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

G. W. Canonica
, F. Blasi
, P. Paggiaro
, G. Senna
, G. Passalacqua
, A. Spanevello
, S. Aliberti
, D. Bagnasco
, M. Bonavia
, M. Bonini
, L. Brussino
, C. Bucca
, M. F. Caiaffa
, Anna Chiara Calabrese
, G. Camiciottoli
, M. Caminati
, G. E. Carpagnano
, C. Caruso
, S. Centanni
, M. E. Conte

A. G. Corsico, L. Cosmi, M. T. Costantino, N. Crimi, S. D'Alo, M. D'Amato, Giacco S. Del, A. Farsi, E. Favero, Barbaro M. P. Foschino, G. Guarnieri, G. Guida, M. Latorre, Cicero S. Lo, C. Lombardi, L. Macchia, F. Mazza, F. Menzella, M. Milanese, M. Montagni, Paolo Montuschi, E. Nucera, R. Parente, V. Patella, G. Pelaia, L. Pini, F. Puggioni, L. Ricciardi, F. L. M. Ricciardolo, Luca Richeldi, E. Ridolo, G. Rolla, P. Santus, N. Scichilone, G. Spadaro, A. Vianello, V. Viviano, M. R. Yacoub, M. C. Zappa, E. Heffler^*

^*Autore corrispondente per questo lavoro

University of Milan
University of Pisa
University of Verona
San Martino Hospital Genoa
University of Insubria
Respiratory Rehabilitation
University of Turin
Azienda Ospedaliera Careggi
University of Florence
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
University of Naples Federico II
University of Cagliari
USL Toscana Centro
Vittorio Veneto Hospital
University of Padua
Allergy and Pneumology Unit
Asst Grande Ospedale Metropolitano Niguarda
Hospital Institute Fondazione Poliambulanza
University of Bari
Respiratory Unit
Santa Maria Nuova Hospital
Pulmonology Unit
UOC Allergology Department
OO.RR. Scuola Medica Salernitana
“Santa Maria Della Speranza” Hospital of Battipaglia
Magna Græcia University
University of Brescia
IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
Humanitas University
University of Messina
University of Parma
University of Palermo
Azienda Ospedaliera Universitaria Federico II
Allergology

Risultato della ricerca: Contributo in rivista › Articolo

2 Citazioni (Scopus)

Abstract

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Rivista	THE WORLD ALLERGY ORGANIZATION JOURNAL
Volume	13
Numero di pubblicazione	10
DOI	https://doi.org/10.1016/j.waojou.2020.100464
Stato di pubblicazione	Pubblicato - 2020

All Science Journal Classification (ASJC) codes

Immunologia e Allergia
Immunologia
Medicina Polmonare e Respiratoria

Keywords

Biologics
Oral corticosteroids
Real-life
Registr
Severe asthma

Accesso al documento

10.1016/j.waojou.2020.100464

Altri file e collegamenti

Cita questo

Canonica, G. W., Blasi, F., Paggiaro, P., Senna, G., Passalacqua, G., Spanevello, A., Aliberti, S., Bagnasco, D., Bonavia, M., Bonini, M., Brussino, L., Bucca, C., Caiaffa, M. F., Calabrese, A. C., Camiciottoli, G., Caminati, M., Carpagnano, G. E., Caruso, C., Centanni, S., ... Heffler, E. (2020). Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). THE WORLD ALLERGY ORGANIZATION JOURNAL, 13(10), N/A-N/A. https://doi.org/10.1016/j.waojou.2020.100464

@article{b465c25ba70c4f059bcdb1b54c4dfac5,

title = "Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)",

abstract = "According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.",

keywords = "Biologics, Oral corticosteroids, Real-life, Registr, Severe asthma, Biologics, Oral corticosteroids, Real-life, Registr, Severe asthma",

author = "Canonica, \{G. W.\} and F. Blasi and P. Paggiaro and G. Senna and G. Passalacqua and A. Spanevello and S. Aliberti and D. Bagnasco and M. Bonavia and M. Bonini and L. Brussino and C. Bucca and Caiaffa, \{M. F.\} and Calabrese, \{Anna Chiara\} and G. Camiciottoli and M. Caminati and Carpagnano, \{G. E.\} and C. Caruso and S. Centanni and Conte, \{M. E.\} and Corsico, \{A. G.\} and L. Cosmi and Costantino, \{M. T.\} and N. Crimi and S. D'Alo and M. D'Amato and Del, \{Giacco S.\} and A. Farsi and E. Favero and Foschino, \{Barbaro M. P.\} and G. Guarnieri and G. Guida and M. Latorre and Lo, \{Cicero S.\} and C. Lombardi and L. Macchia and F. Mazza and F. Menzella and M. Milanese and M. Montagni and Paolo Montuschi and E. Nucera and R. Parente and V. Patella and G. Pelaia and L. Pini and F. Puggioni and L. Ricciardi and Ricciardolo, \{F. L. M.\} and Luca Richeldi and E. Ridolo and G. Rolla and P. Santus and N. Scichilone and G. Spadaro and A. Vianello and V. Viviano and Yacoub, \{M. R.\} and Zappa, \{M. C.\} and E. Heffler",

year = "2020",

doi = "10.1016/j.waojou.2020.100464",

language = "English",

volume = "13",

pages = "N/A--N/A",

journal = "THE WORLD ALLERGY ORGANIZATION JOURNAL",

issn = "1939-4551",

publisher = "Philadelphia, PA : Lippincott Williams \& Wilkins",

number = "10",

}

Canonica, GW, Blasi, F, Paggiaro, P, Senna, G, Passalacqua, G, Spanevello, A, Aliberti, S, Bagnasco, D, Bonavia, M, Bonini, M, Brussino, L, Bucca, C, Caiaffa, MF, Calabrese, AC, Camiciottoli, G, Caminati, M, Carpagnano, GE, Caruso, C, Centanni, S, Conte, ME, Corsico, AG, Cosmi, L, Costantino, MT, Crimi, N, D'Alo, S, D'Amato, M, Del, GS, Farsi, A, Favero, E, Foschino, BMP, Guarnieri, G, Guida, G, Latorre, M, Lo, CS, Lombardi, C, Macchia, L, Mazza, F, Menzella, F, Milanese, M, Montagni, M, Montuschi, P, Nucera, E, Parente, R, Patella, V, Pelaia, G, Pini, L, Puggioni, F, Ricciardi, L, Ricciardolo, FLM, Richeldi, L, Ridolo, E, Rolla, G, Santus, P, Scichilone, N, Spadaro, G, Vianello, A, Viviano, V, Yacoub, MR, Zappa, MC & Heffler, E 2020, 'Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)', THE WORLD ALLERGY ORGANIZATION JOURNAL, vol. 13, n. 10, pagg. N/A-N/A. https://doi.org/10.1016/j.waojou.2020.100464

TY - JOUR

T1 - Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

AU - Canonica, G. W.

AU - Blasi, F.

AU - Paggiaro, P.

AU - Senna, G.

AU - Passalacqua, G.

AU - Spanevello, A.

AU - Aliberti, S.

AU - Bagnasco, D.

AU - Bonavia, M.

AU - Bonini, M.

AU - Brussino, L.

AU - Bucca, C.

AU - Caiaffa, M. F.

AU - Calabrese, Anna Chiara

AU - Camiciottoli, G.

AU - Caminati, M.

AU - Carpagnano, G. E.

AU - Caruso, C.

AU - Centanni, S.

AU - Conte, M. E.

AU - Corsico, A. G.

AU - Cosmi, L.

AU - Costantino, M. T.

AU - Crimi, N.

AU - D'Alo, S.

AU - D'Amato, M.

AU - Del, Giacco S.

AU - Farsi, A.

AU - Favero, E.

AU - Foschino, Barbaro M. P.

AU - Guarnieri, G.

AU - Guida, G.

AU - Latorre, M.

AU - Lo, Cicero S.

AU - Lombardi, C.

AU - Macchia, L.

AU - Mazza, F.

AU - Menzella, F.

AU - Milanese, M.

AU - Montagni, M.

AU - Montuschi, Paolo

AU - Nucera, E.

AU - Parente, R.

AU - Patella, V.

AU - Pelaia, G.

AU - Pini, L.

AU - Puggioni, F.

AU - Ricciardi, L.

AU - Ricciardolo, F. L. M.

AU - Richeldi, Luca

AU - Ridolo, E.

AU - Rolla, G.

AU - Santus, P.

AU - Scichilone, N.

AU - Spadaro, G.

AU - Vianello, A.

AU - Viviano, V.

AU - Yacoub, M. R.

AU - Zappa, M. C.

AU - Heffler, E.

PY - 2020

Y1 - 2020

N2 - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

AB - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

KW - Biologics

KW - Oral corticosteroids

KW - Real-life

KW - Registr

KW - Severe asthma

KW - Biologics

KW - Oral corticosteroids

KW - Real-life

KW - Registr

KW - Severe asthma

UR - https://publicatt.unicatt.it/handle/10807/163501

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85091219259&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091219259&origin=inward

U2 - 10.1016/j.waojou.2020.100464

DO - 10.1016/j.waojou.2020.100464

M3 - Article

SN - 1939-4551

VL - 13

SP - N/A-N/A

JO - THE WORLD ALLERGY ORGANIZATION JOURNAL

JF - THE WORLD ALLERGY ORGANIZATION JOURNAL

IS - 10

ER -

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo